Modulation of stress-induced and stimulated hyperprolactinemia with the group II metabotropic glutamate receptor selective agonist, LY379268

Neuropharmacology

Volumn 43, Issue 5, 2002, Pages 799-808

  Johnson, M P ^a   Chamberlain, M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Alpha methyl p tyrosine; DOI; GABA; LY341495; LY379268; mGlu2 3

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ESTROGEN; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; ISOPROTEIN; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METIROSINE; PROLACTIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARCUATE NUCLEUS; ARTICLE; CATECHOLAMINE DEPLETION; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HYPERPROLACTINEMIA; HYPOTHALAMUS NUCLEUS; IMMOBILIZATION STRESS; MALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RAT; REGULATORY MECHANISM; TREATMENT OUTCOME; TUBEROHYPOPHYSEAL TRACT;

ALPHA-METHYLTYROSINE; AMINO ACIDS; AMPHETAMINE; AMPHETAMINES; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ESTROUS CYCLE; FEMALE; HYPERPROLACTINEMIA; MALE; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RESTRAINT, PHYSICAL; STRESS, PSYCHOLOGICAL;

EID: 0036802189     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00142-9     Document Type: Article

References (55)

1. Abbud R., Smith M.S. Altered luteinizing hormone and prolactin responses to excitatory amino acids during lactation. Neuroendocrinology. 58:1993;454-464.
2. Afione S., Duvilanski B., Seilicovich A., Lasaga M., Diaz M.C., Debeljuk L. Effects of serotonin on the hypothalamic-pituitary GABAergic system. Brain Research Bulletin. 25:1990;245-249.
3. Aguilar E., Tena-Sempere M., Aguilar R., Gonzalez D., Pinilla L. Interactions between N-methyl-D-aspartate, nitric oxide and serotonin in the control of prolactin secretion in prepubertal male rats. European Journal of Endocrinology. 137:1997;99-106.
4. Ben-Jonathan N. Dopamine: a prolactin-inhibiting hormone. Endocrine Review. 6:1985;564-589.
5. Bhat G.K., Mahesh V.B., Chu Z.W., Chorich L.P., Zamorano P.L., Brann D.W. Localization of the N-methyl-D-aspartate R1 receptor subunit in specific anterior pituitary hormone cell types of the female rat. Neuroendocrinology. 62:1995;178-186.
6. Boissin-Agasse L., Tappaz M., Roch G., Gril C., Boissin J. Morphofunctional evidence for the involvement of hypothalamic dopaminergic and GABAergic neurons in the mechanisms of photoperiod-dependent prolactin release in the mink. Neuroendocrinology. 53:1991;537-542.
7. Bond A., Jones N.M., Hicks C.A., Whiffin G.M., Ward M.A., O'Neill M.F., Kingston A.E., Monn J.A., Ornstein P.L., Schoepp D.D., Lodge D., O'Neill M.J. Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo. Journal of Pharmacology and Experimental Therapeutics. 294:2000;800-809.
8. Bond A., Ragumoorthy N., Monn J.A., Hicks C.A., Ward M.A., Lodge D., O'Neill M.J. LY379268, a potent and selective Group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischaemia. Neuroscience Letters. 273:1999;191-194.
9. Cai Z., Xiao F., Fratkin J.D., Rhodes P.G. Protection of neonatal rat brain from hypoxic-ischemic injury by LY379268, a Group II metabotropic glutamate receptor agonist. Neuroreport. 10:1999;3927-3931.
10. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. Journal of Pharmacology & Experimental Therapeutics. 291:1999;161-170.
11. Cartmell J., Monn J.A., Schoepp D.D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology (Berl). 148:2000;423-429.
12. Cartmell J., Monn J.A., Schoepp D.D. The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. European Journal of Pharmacology. 400:2000;221-224.
13. Cartmell J., Monn J.A., Schoepp D.D. Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch Pharmacol. 361:2000;39-46.
14. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., Schoepp D.D. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine,3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. Journal of Neurochemistry. 75:2000;1147-1154.
15. Cartmell J., Schoepp D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. Journal of Neurochemistry. 75:2000;889-907.
16. Coccaro E.F., Kavoussi R.J., Oakes M., Cooper T.B., Hauger R. 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Psychopharmacology (Berl). 126:1996;24-30.
17. Conn P., Freeman M., Neuroendocrinology in Physiology and Medicine. 2000;Totowa, New Jersey, Humana Press.
18. Demarest K.T., Riegle G.D., Moore K.E. Pharmacological manipulation of anterior pituitary dopamine content in the male rat: relationship to serum prolactin concentration and lysosomal enzyme activity. Endocrinology. 115:1984;493-500.
19. Ferreira S.A., Browning D.A., Scott C.J., Kuehl D.E., Jackson G.L. Effect of infusing gamma-aminobutyric acid receptor agonists and antagonists into the medial preoptic area and ventromedial hypothalamus on prolactin secretion in male sheep. Endocrine. 9:1998;303-312.
20. Fuller R.W., Perry K.W., Clemens J.A. Elevation of 3, 4-dihydroxyphenylacetic acid concentrations in rat brain and stimulation of prolactin secretion by fenfluramine: evidence for antagonism at dopamine receptor sites. Journal of Pharmacy and Pharmacology. 28:1976;643-644.
21. Gonzalez L.C., Pinilla L., Tena-Sempere M., Aguilar E. Regulation of growth hormone secretion by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in infantile, prepubertal, and adult male rats. Endocrinology. 140:1999;1279-1284.
22. Gonzalez L.C., Pinilla L., Tena-Sempere M., Aguilar E. Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the control of prolactin, growth hormone and gonadotropin secretion in prepubertal rats. Journal of Endocrinology. 162:1999;417-424.
23. Gonzalez L.C., Pinilla L., Tena-Sempere M., Aguilar E. Regulation of prolactin secretion by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in male rats. Journal of Endocrinology. 166:2000;669-675.
24. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for Group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 284:1998;651-660.
25. Horowski R., Graf H.J. Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat. Neuroendocrinology. 22:1976;273-286.
26. Kingston A.E., Ornstein P.L., Wright R.A., Johnson N.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of Group II metabotropic glutamate receptors. Neuropharmacology. 37:1998;1-12.
27. Liang S.L., Pan J.T. An endogenous serotonergic rhythm acting on 5-HT(2A) receptors may be involved in the diurnal changes in tuberoinfundibular dopaminergic neuronal activity and prolactin secretion in female rats. Neuroendocrinology. 72:2000;11-19.
28. Liu X.B., Munoz A., Jones E.G. Changes in subcellular localization of metabotropic glutamate receptor subtypes during postnatal development of mouse thalamus. Journal of Comparative Neurology. 395:1998;450-465.
29. Login I.S. Direct stimulation of pituitary prolactin release by glutamate. Life Science. 47:1990;2269-2275.
30. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a Group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
31. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L. Jr, Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for Group II metabotropic glutamate receptors. Journal of Medical Chemistry. 42:1999;1027-1040.
32. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active Group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Journal of Medicinal Chemistry. 40:1997;528-537.
33. Moore K.E., Demarest K.T., Johnston C.A. Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Federation Proceedings. 39:1980;2912-2916.
34. Ohishi H., Akazawa C., Shigemoto R., Nakanishi S., Mizuno N. Distributions of the mRNAs for L-2-amino-4-phosphonobutyrate-sensitive metabotropic glutamate receptors, mGluR4 and mGluR7, in the rat brain. Journal of Comparative Neurology. 360:1995;555-570.
35. Ohishi H., Neki A., Mizuno N. Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse: an immunohistochemical study with a monoclonal antibody. Neuroscience Research. 30:1998;65-82.
36. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018.
37. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: an in situ hybridization study. Journal of Comparative Neurology. 335:1993;252-266.
38. Parker S.L., Crowley W.R. Stimulation of oxytocin release in the lactating rat by central excitatory amino acid mechanisms: evidence for specific involvement of R,S-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-sensitive glutamate receptors. Endocrinology. 133:1993;2847-2854.
39. Pechnick R.N., George R., Poland R.E. Characterization of the effects of the acute and repeated administration of MK-801 on the release of adrenocorticotropin, corticosterone and prolactin in the rat. European Journal of Pharmacology. 164:1989;257-263.
40. Petralia R.S., Wang Y.X., Niedzielski A.S., Wenthold R.J. The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience. 71:1996;949-976.
41. Quattrone A., Schettini G., Di Renzo G.F., Preziosi P. Pharmacological evidence of an interaction between serotonergic and dopaminergic neurons in the control of prolactin secretion in male rats. Archives Internationales de Pharmacodynamie et de Therapie. 238:1979;42-49.
42. Rubin R.T., Poland R.E., O'Connor D., Gouin P.R., Tower B.B. Selective neuroendocrine effects of low-dose haloperidol in normal adult men. Psychopharmacologia. 47:1976;135-140.
43. Salt T.E., Turner J.P. Modulation of sensory inhibition in the ventrobasal thalamus via activation of Group II metabotropic glutamate receptors by 2R,4R-aminopyrrolidine-2,4-dicarboxylate. Experimental Brain Research. 121:1998;181-185.
44. Scarduelli C., Mattei A.M., Brambilla G., Zavaglia C., Adelasco P., Cavioni V., Ferrari C. Effect of fenfluramine oral administration on serum prolactin levels in healthy and hyperprolactinemic women. Gynecological and Obstetric Investigation. 19:1985;92-96.
45. Schoepp D.D., Jane D.E., Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology. 38:1999;1431-1476.
46. Shekhar A., Keim S.R. LY354740, a potent Group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology. 39:2000;1139-1146.
47. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. Journal of Neuroscience. 17:1997;7503-7522.
48. Tamaru Y., Nomura S., Mizuno N., Shigemoto R. Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: Differential localization relative to pre- and postsynaptic sites. Neuroscience. 106:2001;481-503.
49. Tappaz M.L., Bosler O., Paut L., Berod A. Glutamate decarboxylase-immunoreactive boutons in synaptic contacts with hypothalamic dopaminergic cells: a light and electron microscopy study combining immunocytochemistry and radioautography. Neuroscience. 16:1985;111-122.
50. Van den Pol A.N. Metabotropic glutamate receptor mGluR1 distribution and ultrastructural localization in hypothalamus. Journal of Comparative Neurology. 349:1994;615-632.
51. Van den Pol A.N., Kogelman L., Ghosh P., Liljelund P., Blackstone C. Developmental regulation of the hypothalamic metabotropic glutamate receptor mGluR1. Journal of Neuroscience. 14:1994;3816-3834.
52. Van den Pol A.N., Romano C., Ghosh P. Metabotropic glutamate receptor mGluR5 subcellular distribution and developmental expression in hypothalamus. Journal of Comparative Neurology. 362:1995;134-150.
53. Wagner E.J., Goudreau J.L., Moore K.E., Lookingland K.J. GABAergic regulation of tuberoinfundibular dopaminergic neurons in the male rat. Brain Research Bulletin. 659:1994;194-200.
54. Wagner E.J., Moore K.E., Lookingland K.J. Sexual differences in N-methyl-D-aspartate receptor-mediated regulation of tuberoinfundibular dopaminergic neurons in the rat. Brain Research Bulletin. 611:1993;139-146.
55. Zelena D., Makara G.B., Jezova D. Simultaneous blockade of two glutamate receptor subtypes (NMDA and AMPA) results in stressor-specific inhibition of prolactin and corticotropin release. Neuroendocrinology. 69:1999;316-323.